The global contrast media injectors market size was estimated at USD 2.08 billion in 2024 and is projected to reach USD 3.75 billion by 2030, growing at a CAGR of 10.87% from 2025 to 2030. The market is experiencing significant growth driven by growing demand for imaging tests, technological advancements, and minimally invasive procedures.
According to the data published by the CDC in February 2024, among 129 million adults in the U.S., roughly 52% live with at least one major chronic disease. Additionally, around 27% of adults, or approximately 68 million people, suffer from multiple chronic conditions, with higher rates observed among older adults and women.
The growing demand for imaging tests is a key driver fueling the increased use of contrast media injectors. As the prevalence of chronic diseases such as cancer, cardiovascular conditions, and neurological disorders rises, more patients require advanced diagnostic imaging to detect, monitor, and manage these illnesses. According to NHS England, 47.2 million imaging tests were conducted only in England till March 2024 from June 2023. The pie chart below depicts imaging tests carried out in England in May 2024:
Moreover, the rising prevalence of chronic diseases, including cancer, neurological disorders, and heart conditions, is projected to boost the demand for contrast media injectors in North America. According to data published by Brain Injury Canada in March 2025, over 10 million Canadians are currently affected by neurological conditions, indicating a substantial patient population in need of diagnostic imaging. Contrast media injectors are crucial in enhancing image clarity during neurological procedures. As a result, their adoption is anticipated to rise sharply, leading to improved diagnosis, treatment planning, and patient outcomes in neurological care.
The market is in a high-growth phase, accelerating the expansion rate. The contrast media injectors industry is characterized by high growth owing to the rising number of chronic diseases and the growing launches of syringeless products.
The contrast media injector market is witnessing significant innovation, including syringeless systems and dual-head injectors. For instance, in December 2024, Bracco Diagnostics Inc. announced the launch of Max 3,a syringeless injector for magnetic resonance imaging (MRI) procedures. Continuous R&D efforts aim to develop more innovative and patient-friendly devices, strengthening market competitiveness and growth potential.
Strict regulatory standards from bodies like the FDA and EMA ensure the safety and efficacy of contrast media injectors. Compliance with these regulations can delay product launches but ultimately enhance patient safety and trust. Regulatory approvals also create barriers to entry, favoring established players with resources for thorough testing and certification.
The contrast media injector market has seen moderate merger and acquisition activities as companies seek to expand portfolios and geographic reach. For example, in November 2023, Bracco and Ulrich GmbH Co KG announced a long-term partnership to introduce a Bracco-branded, state-of-the-art MR injector to the U.S. through an exclusive private label agreement.
Regional expansion is a key strategy for market players, focusing on emerging economies with growing healthcare infrastructure, such as Asia-Pacific and Latin America. The increasing partnerships with regional healthcare providers help companies tap into unmet demand, driving revenue growth and global market penetration.
The consumables segment dominated the market in 2024, driven by continuous demand for single-use and replaceable components such as syringes, tubing, and contrast media cartridges. Furthermore, the frequent replacement cycle drives recurring revenue, making this segment a major market contributor. Additional drivers include increased adoption of contrast media injector consumables, improved accessibility, and the growing global prevalence of chronic diseases, all of which are anticipated to contribute significantly to the segment’s sustained growth.
The injector systems segment is the fastest growing, with a CAGR of 10.94% in the contrast media injector market, driven by the increasing adoption of advanced and automated injection devices in diagnostic imaging. These systems enable precise and controlled delivery of contrast agents, improving image quality and patient safety. Growing demand for minimally invasive procedures and rising investments in healthcare infrastructure further propel this segment. Additionally, technological advancements such as smart injectors with real-time monitoring and integration with imaging equipment enhance clinical workflow efficiency, making injector systems indispensable in modern medical imaging, thereby dominating the market share.
The single-head injector segment dominated the contrast media injector market in 2024 due to its widespread use in routine diagnostic imaging procedures. These injectors offer simplicity, reliability, and cost-effectiveness, making them a preferred choice in many healthcare settings. They are commonly used in lower-volume procedures and offer a straightforward solution for contrast delivery in many diagnostic settings.
The syringeless injector is the fastest-growing segment among other injector types, with a CAGR of 12.8% over the forecast period, driven by its ability to reduce contrast media waste and minimize the risk of contamination. Several companies are receiving regulatory approval for the syringeless injectors. For instance, in December 2024, Bracco Diagnostics received U.S. FDA 510(k) clearance for its Max 3 contrast media injector, designed for magnetic resonance imaging (MRI) procedures. The convenience and enhanced infection control offered by syringeless injectors make them increasingly preferred in hospitals and imaging centers, fueling rapid segment expansion.
The radiology segment holds the largest share of 45.47% in 2024 due to the high volume of imaging procedures such as CT scans, MRIs, and angiography performed in radiology departments. For instance, according to NHS England, 0.67 million CT scans and 0.39 million MRIs were performed in January 2025. These procedures rely heavily on the precise and controlled delivery of contrast agents to enhance image quality for accurate diagnosis. The increasing prevalence of chronic diseases and rising demand for advanced diagnostic imaging drive growth in this segment.
The interventional cardiology segment is the fastest-growing segment in the contrast media injector market, driven by the increasing number of minimally invasive cardiovascular procedures such as angioplasty and stenting. Precise contrast media delivery is essential in these procedures to accurately visualize blood vessels and guide interventions. The increasing prevalence of cardiovascular diseases, including coronary artery disease and heart valve disorders, has significantly contributed to the growth of this segment. For instance, according to a CDC report published in September 2024, heart valve disease affects over 5 million individuals annually in the U.S.
The hospitals segment accounts for the largest share, 69.26%, in 2024 and is among the fastest-growing segments in the market due to the high volume of diagnostic imaging and interventional procedures performed in these settings. Hospitals offer comprehensive imaging services such as CT, MRI, and angiography, which require precise and efficient contrast media delivery. Increasing patient inflow, rising prevalence of chronic diseases, and growing investments in advanced healthcare infrastructure drive demand.
The second fastest-growing segment in the contrast media injectors market is diagnostic centers, driven by increasing demand for advanced imaging services and the need for efficient, precise contrast delivery in outpatient and specialized care settings. These centers benefit from automated injectors that enhance workflow, reduce errors, and improve image quality, making them preferred environments for such technology.
North America accounted for the largest share, 38.87%, in the market in 2024, driven by rising demand for advanced imaging procedures. For instance, 40 million MRI scans are performed annually in the U.S. In addition, continuous technological advancements and strong healthcare infrastructure further fuel market growth, supporting enhanced diagnostic accuracy and workflow efficiency.
The U.S. contrast media injectors market is expected to grow significantly due to the rising prevalence of chronic diseases, increasing demand for minimally invasive procedures, and advancements in imaging technologies. Some of the players operating in the U.S. include GE Healthcare, Bracco, and Medtron AG. These players introduce innovative products such as syringeless systems to enhance precision and reduce waste.
The European contrast media injectors market is experiencing significant growth, driven by the rising prevalence of cancer and cardiovascular diseases, which are increasing the demand for advanced diagnostic imaging. Syringeless contrast media injectors are gaining rapid adoption, especially in high-volume regional imaging centers. Technological advancements continue to support this trend-for instance, in February 2025, Bayer announced pipeline developments within its radiology portfolio focused on enhancing contrast media injector technologies.
The UK contrast media injectors market is witnessing steady growth, fueled by increased NHS investments in diagnostic imaging and the integration of advanced injector technologies. Innovations such as syringeless systems and automated dose management are improving diagnostic precision and patient safety, further supporting modern contrast delivery solutions adoption across healthcare facilities.
The contrast media injectors market in France is experiencing strong growth, driven by rising demand for advanced diagnostic imaging in both radiology and interventional cardiology. This trend is further supported by the country’s aging population, which is contributing to a higher incidence of chronic conditions that require frequent imaging procedures. As a result, the need for efficient and precise contrast delivery systems continues to grow across France healthcare facilities.
The Asia Pacific region is one of the fastest-growing markets during the forecast period, driven by a rapidly aging population and rising demand for minimally invasive diagnostic procedures. Technological advancements, including automation, syringeless systems, and dual-head injectors, are improving imaging accuracy and enhancing patient safety, further accelerating the adoption of advanced contrast media injectors across the region.
The China contrast media injectors market is witnessing robust growth, fueled by the rising prevalence of chronic diseases, a rapidly aging population, and expanding healthcare investments. Government initiatives such as the “Healthy China 2030” plan are enhancing diagnostic infrastructure and access to advanced imaging technologies. These efforts are driving demand for efficient contrast delivery systems across hospitals and diagnostic centers nationwide.
The India contrast media injectors market is experiencing strong growth, driven by several key factors. The rising burden of chronic diseases such as cancer and cardiovascular disorders is increasing the demand for advanced diagnostic imaging. Additionally, growing awareness of early disease detection, expanding healthcare infrastructure, and increased government spending on public health fuel market expansion. Adopting modern imaging technologies in public and private healthcare facilities and the rising number of diagnostic centers further support the market's growth.
The Latin America contrast media injectors market is driven by a rising burden of chronic diseases and rising demand for diagnostic devices. Investments in modern medical facilities and government initiatives to improve healthcare access are boosting the adoption of contrast media injectors in the region.
The Middle East and Africa contrast media injectors market is expanding, driven by a high disease burden, increasing demand for health insurance coverage, and increasing privatization in healthcare.
The contrast media injectors market in the UAE is experiencing robust growth, driven by rising chronic disease prevalence, expanding healthcare infrastructure, and increasing demand for minimally invasive diagnostic procedures. Strategic partnerships and new product launches, such as syringeless injectors, strengthen market presence.
Shenzhen Boon Medical Supply Co., Ltd., Bayer, Bracco Diagnostics Inc., ulrich GmbH & Co. KG, Guerbet LLC, B.Braun SE, Shenzhen Antmed Co., Ltd., Ecomed Solutions, and Siemens Medical Solutions USA, Inc. are key players in the contrast media injectors market. They compete by focusing on product innovation, forming strategic partnerships, and expanding their global footprint. These efforts help them meet the growing demand for advanced and reliable contrast media injectors worldwide.
The following are the leading companies in the contrast media injectors market. These companies collectively hold the largest market share and dictate industry trends.
In April 2025, Bayer and Siemens Healthineers introduced MEDRAD Centargo, an automated contrast injection system designed to reduce turnaround times between scans and minimize manual tasks for technologists. This innovation allows medical staff to focus more on patient care, enhancing efficiency and improving overall workflow in diagnostic imaging procedures.
In December 2024, Bracco Diagnostics Inc., the U.S. arm of Bracco Imaging S.p.A., partnered with German medical device maker ulrich GmbH & Co. KG to announce FDA clearance of the Bracco Max 3. This rapid exchange, syringeless injector is designed for magnetic resonance imaging (MRI) procedures, enhancing efficiency and ease of contrast delivery in diagnostic imaging.
Report Attribute |
Details |
Market size value in 2025 |
USD 2.24 billion |
Revenue forecast in 2030 |
USD 3.75 billion |
Growth rate |
CAGR of 10.87% from 2025 to 2030 |
Base year for estimation |
2024 |
Actual data |
2018 - 2023 |
Forecast period |
2025 - 2030 |
Report updated |
June 2025 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, type, application, end use, and region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa (MEA) |
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Shenzhen Boon Medical Supply Co., Ltd.; Bayer; Bracco Diagnostics Inc.; ulrich GmbH & Co. KG; Guerbet LLC; B.Braun SE; Shenzhen Antmed Co., Ltd.; Ecomed Solutions; Siemens Medical Solutions USA, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global contrast media injectors market report on the basis of product, type, application, end use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Injector Systems
CT injector systems
MRI injector systems
Cardiovascular/angiography injector systems
Consumables
Tubing
Syringe
Others
Type Outlook (Revenue, USD Million, 2018 - 2030)
Single Head Injectors
Dual-Head Injectors
Syringeless Injectors
Application Outlook (Revenue, USD Million, 2018 - 2030)
Radiology
Interventional Cardiology
Interventional Radiology
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Diagnostic Centers
Ambulatory Surgery Centers
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global contrast media injectors market size was estimated at USD 2.08 billion in 2024 and is expected to reach USD 2.24 billion in 2025.
b. The global contrast media injectors market is expected to grow at a compound annual growth rate of 10.87% from 2024 to 2030 to reach USD 3.75 billion by 2030.
b. The consumables segment dominated the market in 2024, driven by continuous demand for single-use and replaceable components such as syringes, tubing, and contrast media cartridges.
b. Some key players operating in the contrast media injectors market include Shenzhen Boon Medical Supply Co., Ltd., Bayer, Bracco Diagnostics Inc, ulrich GmbH & Co.KG, Guerbet LLC, B.Braun SE, Shenzhen Antmed Co., Ltd., Ecomed Solutions, and Siemens Medical Solutions USA, Inc.
b. Key factors that are driving the contrast media injectors market growth include technological advancements and increasing demand for minimally invasive surgeries.
NEED A CUSTOM REPORT?
We offer custom report options, including stand-alone sections and country-level data. Special pricing is available for start-ups and universities.
Request CustomizationWe are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."